Overview of Rogastril Plus

Property	Description
Active ingredient	Cinitapride, Simethicone
Form	Tablet, Oral Suspension
Pharmacological class	Gastroprokinetic Agent and Antiflatulent Combination
General purpose	Relief of bloating and motility disturbances
Origin	Synthetic (Cinitapride), Non-systemic/Physical Agent (Simethicone)

What Pharmacological Class Does Rogastril Plus Belong To?

Rogastril Plus is a fixed-dose combination medicine classified within the Gastroprokinetic Agent and Antiflatulent Combination pharmacological class. This structure ensures the medicine addresses two primary aspects of gastrointestinal distress simultaneously: impaired movement and excess gas content. The combination is clinically recognized for integrating these two approaches to enhance overall symptomatic relief. The strategic pairing of a motility agent with an antiflatulent sets this formulation apart from single-ingredient treatments.

Composition: The Active Components and Dosage Form

The orally administered preparation contains the two active ingredients, Cinitapride and Simethicone. Cinitapride, a synthetic benzamide derivative, acts as the prokinetic component, while Simethicone is a physically active silicone compound that functions locally. Simethicone is biologically inert and is notably not systemically absorbed from the gastrointestinal tract, ensuring its action is confined to the digestive lumen. Rogastril Plus is available in common oral forms, including Tablet and Oral Suspension, for administration.

What is the General Purpose of this Combination Medicine?

The general purpose of Rogastril Plus is to relieve symptoms of discomfort that typically arise from both sluggish gastrointestinal movement and the physical accumulation of gas. By enhancing the organized muscular contractions, or motility, while simultaneously reducing the surface tension of trapped gas bubbles, the medicine aids in the body’s natural processes of accelerating intestinal transit and facilitating gas elimination. This integrated approach generally helps to relieve feelings of bloating, pressure, and the sense of fullness associated with flatulence and compromised gut movement.

What side effects are possible with Rogastril Plus?

Possible Side Effects and Safety Information

The safety profile of Rogastril Plus, a combination of Cinitapride and Simethicone, is documented by official regulatory bodies, classifying adverse reactions by frequency and affected body systems. Simethicone, due to its non-systemic absorption, contributes minimally to the systemic side effects, which are primarily attributed to the prokinetic agent, Cinitapride.

Officially Documented Adverse Reactions by Frequency

Frequency Classification	Documented Effects
Common	Drowsiness (Sedation), Diarrhoea
Very Rare	Cutaneous reactions (e.g., rash), Angioedema, Gynaecomastia, Galactorrhoea

The safety profile also details effects on specific physiological systems. Nervous system disorders may include drowsiness and extrapyramidal reactions (involuntary movements). Reactions affecting the Reproductive system and breast disorders may involve Gynaecomastia (male breast development) and Galactorrhoea (spontaneous milk flow), which are generally classified as very rare.

Special Safety Considerations and Restrictions

The official label includes specific cautions related to patient populations and duration of use. Older adults may face an increased risk of Tardive Dyskinesia when treatment is prolonged. Use is not recommended during pregnancy and lactation due to limited safety data. The medicine is contraindicated in patients with conditions where stimulating gastrointestinal motility could be harmful, such as gastrointestinal haemorrhage, obstruction, or perforation. Additionally, it is noted that the medicine can enhance the sedative effects of other depressants and may alter the absorption of certain co-administered oral medications.

Overdose and Emergency Response

The official regulatory profile for Rogastril Plus details overdose information primarily based on the systemic component, Cinitapride. Overdose is characterized by Central Nervous System (CNS) manifestations that typically include drowsiness, confusion, and disorientation. A severe outcome documented in regulatory sources is the occurrence of extrapyramidal effects or reactions, which involve involuntary muscular movements, often affecting the head, neck, and tongue. These neurological manifestations require immediate and specific medical intervention.

In the event of a suspected overdose, it is mandated that patients seek immediate medical attention and contact emergency services. The Simethicone component is considered non-systemic and does not contribute significantly to systemic overdose toxicity. Regulatory documentation confirms that no specific antidote is known for this overdose.

Consequently, management is entirely symptomatic and supportive. The official procedures described may include gastric lavage if neurological symptoms persist following discontinuation of the medicine. The administration of specific pharmacological treatment is required for persistent extrapyramidal effects, typically using agents such as antiparkinsonians or anticholinergics. Continuous hospital monitoring is necessary to manage and stabilize these severe neurological symptoms and oversee the required supportive measures.

Therapeutic Uses of Rogastril Plus

Rogastril Plus is commonly used to help with symptom clusters that may become intense or disruptive, particularly those linked to organ-specific functional stress. It is generally applied in conditions characterized by periods of heightened symptoms, and may help patients cope more steadily with symptom fluctuations.

The medication is applied across domains where additional symptomatic support is needed, addressing symptoms related to physical discomfort in conditions such as functional dyspepsia, symptoms of delayed gastric emptying, and the management of gas-related distress. This is relevant in contexts involving heightened systemic burden where symptoms of indigestion and abdominal pressure co-exist. The treatment is applicable within clinical settings that involve acute or disruptive symptom patterns, and supports general well-being during symptomatic phases.

This treatment provides support that helps ease the overall symptom burden. It is often used when symptoms intensify and supportive relief is needed, assisting with maintaining functional stability.

Quick Fact: Relief for Bloating and Postprandial Fullness The medication is relevant for managing symptom clusters that interfere with daily comfort, including the painful pressure of trapped wind and the discomfort of feeling uncomfortably full shortly after eating.

Eligibility and Restrictions for Use

Population Eligibility for Rogastril Plus

The eligibility for using Rogastril Plus (Cinitapride/Simethicone) is strictly defined by regulatory guidelines, primarily based on the restrictions associated with the systemic component, Cinitapride. The medicine is generally approved for use in adult patients.

Populations Contraindicated (Must Not Use)

Official regulatory documents explicitly state that Rogastril Plus must not be administered to patients with conditions where stimulating gastrointestinal motility is detrimental:

Gastrointestinal integrity: Patients with confirmed hemorrhage, mechanical obstruction, or perforation.
Neurological history: Individuals with a history of proven neuroleptic-induced tardive dyskinesia.
Hypersensitivity: Patients with known hypersensitivity to Cinitapride or any of the product’s excipients.

Populations with Restricted or Conditional Use

Use is formally subject to caution or is not advisable in the following groups due to lack of established data or potential risk, as stated in regulatory labeling:

Age: Use is not advisable in children and adolescents due to a lack of regulatory experience in these age groups.
Organ Function: Use must proceed with caution in the elderly and in patients with impaired liver or kidney function.
Physiological Status: Use is not recommended as a precautionary measure during pregnancy or lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Rogastril Plus details interaction patterns primarily linked to the systemic component, Cinitapride, which is a prokinetic agent. The non-systemic component, Simethicone, is associated with minimal risk of systemic interaction.

Pharmacokinetic and Exposure Interactions

Co-administration with strong CYP3A4 inhibitors (such as Ketoconazole) may alter the metabolism of Cinitapride, potentially increasing its systemic exposure. Conversely, the prokinetic action of Cinitapride can reduce the absorption rate of other orally co-administered medicines, which is a consideration for drugs with narrow therapeutic windows, such as Digoxin.

Pharmacodynamic and Substance Interactions

Central Nervous System (CNS) Depressants: Co-administration with tranquillisers, hypnotics, narcotics, or alcohol is documented to enhance the sedative effects of Cinitapride.
Antagonistic Agents: The prokinetic effect may be reduced by the co-administration of atropinic anticholinergics or opioid analgesics.
Dopamine Antagonists: The use of Rogastril Plus may enhance the CNS effects of other dopamine antagonists, such as Phenothiazines.

Interaction-Related Restrictions

The medicine is restricted for use in patients with conditions where motility stimulation is harmful, including established gastrointestinal hemorrhage, obstruction, or perforation. Caution against prolonged use is noted for elderly patients due to increased neurological risk associated with the drug’s action.

Mechanism of Action

The prokinetic component, Cinitapride, works by regulating key signaling within the Enteric Nervous System. It acts as an agonist at excitatory 5 -HT4 serotonin receptors to promote Acetylcholine release, while simultaneously functioning as an antagonist at inhibitory Dopamine D2 receptors. This dual-action mechanism reduces inhibitory dopaminergic influence and increases excitatory cholinergic signaling, enhancing the amplitude and organization of gastrointestinal smooth muscle contractions.

The antiflatulent component, Simethicone, operates locally within the gut lumen through a physicochemical mechanism. Being biologically inert, it functions as a surfactant to significantly reduce the surface tension of trapped gas bubbles. This action causes the numerous small, foamy gas bubbles to coalesce rapidly into larger pockets, transforming them into a state that is physiologically easier to propel and clear.

The combined mechanism results in a complementary action: Cinitapride provides a propulsive mechanism by enhancing peristalsis, while Simethicone provides the physical substrate (coalesced gas) for that propulsive mechanism to clear. This integrated cascade affects both the motor dysfunction and the physical structure of gaseous foam simultaneously, and promotes a more coordinated state of intestinal transit.

Dosage and Administration Information

The administration of Rogastril Plus (Cinitapride and Simethicone) is governed by instructions centered on the precise timing and dosage of the Cinitapride component. The medicine is exclusively administered via the oral route, utilizing the available Tablet or Oral Suspension forms. The standard prescribed regimen for adults involves a dose equivalent to 1 mg of Cinitapride per intake.

Standard Administration Protocol

The documentation specifies a dosing frequency of three times a day (TID). This schedule is tied directly to the ingestion of food, requiring the medicine to be taken precisely 15 minutes before each of the three main meals. The total daily intake is strictly limited, with the maximum dose for the Cinitapride component restricted to 3 mg per 24-hour period, and increasing this dose is not advised. Tablets should be swallowed whole without being crushed or chewed, and if a dose is missed, patients are generally instructed to skip the missed dose and resume the normal schedule.

Use Duration and Specific Populations

Rogastril Plus is intended for use as a short-term course of therapy; clinical contexts frequently reference a duration of 4 weeks for initial assessment of response. Labeling provides specific guidance regarding age groups: the standard adult dose applies to patients over 20 years of age. Use in children or adolescents is not advisable due to a lack of established data concerning administration in these populations. The administration protocol is designed to ensure the prokinetic agent is active at the beginning of the digestive process.

Recent Clinical Evidence

Evidence for Use in Functional Dyspepsia and Symptom Clusters

The research informing the evidence base for Rogastril Plus has primarily been evaluated in studies exploring how symptoms change over time in individuals diagnosed with functional dyspepsia, a condition characterized by fluctuating or episodic manifestations of discomfort. The evidence base includes Randomized Controlled Trials (RCTs) that compare the medicine's active components against a placebo or an active comparator, as well as multi-center observational studies.

Research examined how these studies monitored specific patient-reported outcomes describing perceived discomfort, such as postprandial fullness, bloating, and general upper abdominal distress, in adult patients with mild to moderate forms of the condition. The findings describe patterns observed in the studies regarding overall symptom changes, but for the fixed-dose combination itself, the evidence is often drawn from the data on its individual active ingredients.

Evidence for Use in Delayed Gastric Emptying

This area of research was studied for its role in conditions characterized by physiological measurement related to Delayed Gastric Emptying. These investigations mainly focused on the prokinetic component, examining its role in conditions involving periods of temporary physiological imbalance. The primary focus was the measurement of gastric emptying half-time. Research describing these physiological changes applies only to the populations studied—adult patients confirmed to have mild to moderate delayed gastric emptying.

Research Gaps and Uncertainty

When reviewing the research, it is important to understand that the typical follow-up durations were limited, focusing on outcomes measured over short-term periods (4 to 8 weeks). Consequently, long-term effects are not fully established in the research literature cited by regulatory agencies, leaving an area where data are still emerging.

Data for certain groups remain insufficient, including for older adults and individuals with co-existing conditions beyond the core functional gastrointestinal issues. The results apply only to the populations studied in the primary clinical trials, and certainty remains low regarding certain group patterns.

Key Studies & References

Efficacy and Safety of Cinitapride Combination in Dyspepsia (NCT01878036)

Frequently Asked Questions (FAQ)

Common questions about Rogastril Plus (FAQ)

Q: What is the main difference between Rogastril Plus and regular Rogastril?

A: Rogastril Plus is officially described as a fixed-dose combination medicine. It contains the motility agent Cinitapride along with the antiflatulent agent Simethicone. The product often referred to as 'regular Rogastril' typically denotes the formulation that contains only the Cinitapride ingredient.

Q: What is the list of conditions Rogastril Plus is approved to treat?

A: Official regulatory documents describe Rogastril Plus as indicated for treating gastrointestinal conditions related to motility disturbances. This includes conditions such as non-ulcer dyspepsia (indigestion), delayed gastric emptying, and Gastroesophageal Reflux Disease (GERD).

Q: How quickly does Rogastril Plus start working after taking it?

A: According to regulatory data on how the drug is processed by the body, the systemic component (Cinitapride) is rapidly absorbed. Maximum concentration levels of the active component in the bloodstream are generally observed around two hours after the dose is administered.

Q: Are there any long-term safety concerns with using Rogastril Plus?

A: The medicine is generally intended for short-term use, and regulatory sources recommend avoiding prolonged treatment. For older adults in particular, prolonged use carries an increased risk of neurological side effects, such as Tardive Dyskinesia.

Q: Is Rogastril Plus safe for use in older adults?

A: Official patient information advises that use in older adults proceeds with caution. This is primarily due to the increased neurological risk associated with the systemic component of the medicine. A healthcare provider may determine that close monitoring is appropriate during the course of treatment for older patients.

Q: Are there any warnings about driving or operating machinery while taking Rogastril Plus?

A: Yes, official warnings exist due to the possibility of side effects. Since the medicine can cause drowsiness or sedation, regulatory agencies advise avoiding activities that require full alertness, such as driving or operating heavy machinery. Patients are advised to wait until they understand how the medicine affects their alertness before engaging in these activities.

Q: If I am taking multiple medications, how can I check for Rogastril Plus interactions?

A: To reliably check for Rogastril Plus interactions, official guidance emphasizes full disclosure of all medications. Patients should provide their complete list of prescription drugs, over-the-counter products, and supplements to a pharmacist or doctor before starting treatment.

Q: Does the research on Rogastril Plus include diverse populations?

A: Official regulatory reviews of the research evidence note that data is limited for certain groups. Specifically, evidence is insufficient for older adults and individuals with complex co-existing conditions. This means the primary evidence applies mainly to the adult populations studied in the initial short-term clinical trials.

Q: Can Rogastril Plus cause changes in mood or behavior?

A: Official documents list central nervous system (CNS) effects such as drowsiness (sedation) and, in very rare cases, involuntary movements. While changes in mood or behavior are not commonly listed, it is advised to consult a healthcare provider if any unusual symptoms are noticed while taking the medicine.

Q: Do I need a prescription to get Rogastril Plus?

A: Yes, according to the official legal classification, the Cinitapride component in Rogastril Plus makes it a prescription-only (Rx) medicine. It cannot be purchased over the counter.

Q: Can Rogastril Plus be used for pain relief?

A: No, the medicine is officially indicated for treating conditions related to motility disturbances in the gut, such as indigestion and reflux. It is not approved or listed in regulatory documents for the treatment of general pain relief.

Q: How long does the effect of Rogastril Plus last?

A: The duration of the therapeutic effect is generally reported to last around eight hours in the body. This characteristic aligns with the typical recommended administration frequency of three times per day.

Q: Does Rogastril Plus cause weight gain?

A: According to official safety information, weight gain is not listed among the commonly reported or documented side effects of Rogastril Plus.

Q: Does Rogastril Plus interact with common over-the-counter pain relievers?

A: Official drug interaction documents mention that taking the medicine with certain pain relievers known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may increase the risk of developing high blood pressure (hypertension). Patients should discuss all over-the-counter products with a healthcare provider.

Q: What foods should I avoid while taking Rogastril Plus?

A: Official regulatory documentation states there are no known direct interactions with food for Rogastril Plus. However, general medical advice for conditions like GERD often suggests avoiding trigger foods that may worsen symptoms.

Q: Is Rogastril Plus addictive?

A: No. The medicine is not listed as a controlled substance and has not been reported in official regulatory documents to be habit-forming or to carry a risk of dependence.

Q: Can I stop taking Rogastril Plus suddenly?

A: Since the medicine is not classified as habit-forming, there are no specific warnings about withdrawal from sudden cessation. Nonetheless, regulatory advice recommends always following the specific directions given by a healthcare provider for stopping treatment.

Q: Can Rogastril Plus affect blood pressure readings?

A: Yes, official interaction documents indicate it may affect blood pressure. It can reduce the effect of certain blood pressure medications and can increase the risk of high blood pressure when taken alongside certain NSAID pain relievers.

Q: What information should I read on the patient information leaflet for Rogastril Plus?

A: The Patient Information Leaflet (PIL) or similar regulatory documents contain all essential details. This includes key information on how to properly use the medicine, a full list of possible side effects, official warnings, and a complete list of all ingredients.

Q: Is it required to have routine monitoring or tests while taking Rogastril Plus?

A: Routine monitoring of liver and kidney function tests may be required if a patient belongs to certain groups. This is typically limited to older patients and individuals with known impaired liver or kidney function.

Q: What should I do if I suspect an interaction between Rogastril Plus and another drug?

A: If a patient suspects they are experiencing an interaction or notice new, unusual symptoms, guidance advises immediately contacting a doctor, pharmacist, or other healthcare professional for instruction.

Q: Is Rogastril Plus a controlled substance?

A: No, this medicine is not classified as a controlled substance. It is listed as a prescription medicine but is not included in US or international schedules for drugs with high abuse potential.

How should Rogastril Plus be stored and disposed of?

Storage Requirements

Official regulatory labeling dictates specific conditions for storing this medicine. The product must be stored at room temperature, generally defined as below 30 C, and should be protected from excessive heat and direct sunlight. It is mandatory to keep the product in its original container and ensure the packaging remains tightly closed to protect it from moisture. To maintain the medicine's stability through the expiration date, these environmental conditions must be strictly followed. The product must not be frozen.

Child Safety and Disposal

For safety, the medication must be stored out of the sight and reach of children. When disposal is necessary, unused or expired product should not be flushed down the toilet or poured into wastewater. Disposal must follow official guidelines, which typically involve utilizing a medicine take-back program or mixing the product with an undesirable substance for secure household trash disposal.

Rogastril Plus